HDI 3000 drives ATL revenue numbers
Ultrasound vendor ATL continues to enjoy strong momentum fromsales of its premium HDI 3000 scanner. The Bothell, WA, companythis month reported year-end financial results that show worldwiderevenues up 9%. For 1995, ATL had revenues of $399.4 million
Ultrasound vendor ATL continues to enjoy strong momentum fromsales of its premium HDI 3000 scanner. The Bothell, WA, companythis month reported year-end financial results that show worldwiderevenues up 9%.
For 1995, ATL had revenues of $399.4 million compared withsales of $366.2 million in 1994. Net income improved sharply,to a net profit of $12 million in 1995 from a net loss of $20.2million in 1994, when ATL took charges relating to its consolidationof Interspec and litigation with SRI International. In 1995, ATLalso enjoyed a one-time benefit of $6.5 million related to a favorablestate sales tax audit and its new joint venture with Hitachi (SCAN11/22/95).
ATL's fourth-quarter numbers show that its momentum increasedas the year drew to a close. Fourth-quarter revenues rose 14%to $119.1 million, compared with $104.7 million in the same periodof 1994. Net income was $12.2 million compared with a net lossof $5.8 million in the fourth quarter of 1994. The Hitachi investmentof $6.2 million was recorded in the fourth quarter of 1995.
The company's growth was due to market acceptance of HDI 3000,as well as strong sales of ATL's mid-range Apogee product linein international markets, according to chairman and CEO DennisFill. ATL this month announced that as of the end of 1995 it hadshipped over 1000 HDI 3000 scanners. The company also said thatit was named as a preferred vendor for radiology ultrasound byUniversity HealthSystem Consortium of Oak Brook, IL.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
